Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioRexis Pharmaceutical
King of Prussia, Pennsylvania, United Statesbiorexis.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioRexis Pharmaceutical was a clinical-stage biopharmaceutical company specializing in the development of long-acting biotherapeutics. The company utilized its proprietary Trans-Rexis platform, which involves fusing therapeutic proteins or peptides to human transferrin to significantly extend their circulating half-life. This technology was designed to create "bio-better" versions of existing drugs with improved dosing schedules and efficacy profiles. BioRexis's lead candidate, BRX-0585, was a long-acting GLP-1 receptor agonist for the treatment of type 2 diabetes. The company was acquired by Pfizer in 2007 to enhance Pfizer's portfolio in metabolic diseases and biologics.
- Therapeutic areas
- Endocrinology
- Modalities
- Recombinant fusion proteinPeptidesProtein
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on BioRexis Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioRexis Pharmaceutical.